LISATA THERAPEUTICS, INC. Research And Development Expense

Quick Answer

LISATA THERAPEUTICS, INC. reported Research And Development Expense of $17.68 million for the year ending 2021.

  • LISATA THERAPEUTICS, INC. showed an increase of +91.1% in Research And Development Expense from 2020 to 2021.
  • This data is from LISATA THERAPEUTICS, INC.'s annual report (Form 10-K), filed with the SEC on March 22, 2022.
  • XBRL data for this metric is available from 2010 to 2021 (12 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Quarterly values from 10-Q filings: Q2 2010: $2.13 million | Q3 2010: $1.68 million | Q1 2011: $2.76 million | Q2 2011: $1.59 million | Q3 2011: $1.54 million | Q1 2012: $1.95 million | Q2 2012: $2.71 million | Q3 2012: $2.83 million | Q1 2013: $3.16 million | Q2 2013: $3.97 million | Q3 2013: $4.49 million | Q1 2014: $4.76 million | Q2 2014: $5.80 million | Q3 2014: $8.47 million | Q1 2015: $6.80 million | Q2 2015: $7.60 million | Q3 2015: $6.32 million | Q1 2016: $5.88 million | Q2 2016: $4.49 million | Q3 2016: $2.96 million | Q1 2017: $3.73 million | Q2 2017: $4.28 million | Q3 2017: $3.19 million | Q1 2018: $2.26 million | Q2 2018: $2.12 million | Q3 2018: $1.70 million | Q1 2019: $2.04 million | Q2 2019: $2.99 million | Q3 2019: $3.00 million | Q1 2020: $1.50 million | Q2 2020: $1.82 million | Q3 2020: $3.03 million | Q1 2021: $5.08 million | Q2 2021: $4.33 million | Q3 2021: $4.13 million | Q1 2022: $3.28 million | Q2 2022: $3.24 million.
  • Over the full 12 years of available data (2010 to 2021), LISATA THERAPEUTICS, INC.'s Research And Development Expense has grown by 130.1%.
  • Historical annual values: Fiscal year 2021: $17.68 million | Fiscal year 2020: $9.25 million | Fiscal year 2019: $10.80 million | Fiscal year 2018: $7.59 million | Fiscal year 2017: $15.84 million | Fiscal year 2016: $16.70 million | Fiscal year 2015: $23.90 million | Fiscal year 2014: $29.19 million | Fiscal year 2013: $16.92 million | Fiscal year 2012: $10.45 million | Fiscal year 2011: $7.72 million | Fiscal year 2010: $7.68 million.
  • Data sourced from SEC EDGAR public filings as of August 6, 2026.

Last verified: